Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.

@article{Gottschalk2004ImatinibC,
  title={Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.},
  author={S. Gottschalk and Nora Anderson and Carsten Hainz and S. Gail Eckhardt and Natalie J. Serkova},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 19},
  pages={6661-8}
}
The therapeutic efficacy of imatinib mesylate (Gleevec) is based on its specific inhibition of the BCR-ABL oncogene protein, a widely expressed tyrosine kinase in chronic myelogenous leukemia (CML) cells. The goal of this study was to evaluate glucose metabolism in BCR-ABL-positive cells that are sensitive to imatinib exposure. Two human BCR-ABL-positive cell lines (CML-T1 and K562) and one BCR-ABL-negative cell line (HC-1) were incubated with different imatinib concentrations for 96 hours… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 94 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…